We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Abbott (ABT - Free Report) closed at $101.88, marking a -2.03% move from the previous day. This move lagged the S&P 500's daily loss of 0.4%. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq lost 0.73%.
The maker of infant formula, medical devices and drugs's stock has dropped by 10.62% in the past month, falling short of the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on April 16, 2026. The company is predicted to post an EPS of $1.15, indicating a 5.5% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $11.02 billion, reflecting a 6.38% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $5.68 per share and a revenue of $47.7 billion, demonstrating changes of +10.29% and +7.62%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0% lower within the past month. Currently, Abbott is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 18.32. This indicates a discount in contrast to its industry's Forward P/E of 18.43.
Investors should also note that ABT has a PEG ratio of 1.65 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.52.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Abbott (ABT) Dips More Than Broader Market: What You Should Know
In the latest trading session, Abbott (ABT - Free Report) closed at $101.88, marking a -2.03% move from the previous day. This move lagged the S&P 500's daily loss of 0.4%. At the same time, the Dow added 0.11%, and the tech-heavy Nasdaq lost 0.73%.
The maker of infant formula, medical devices and drugs's stock has dropped by 10.62% in the past month, falling short of the Medical sector's loss of 10.07% and the S&P 500's loss of 7.34%.
The upcoming earnings release of Abbott will be of great interest to investors. The company's earnings report is expected on April 16, 2026. The company is predicted to post an EPS of $1.15, indicating a 5.5% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $11.02 billion, reflecting a 6.38% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $5.68 per share and a revenue of $47.7 billion, demonstrating changes of +10.29% and +7.62%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Abbott. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0% lower within the past month. Currently, Abbott is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 18.32. This indicates a discount in contrast to its industry's Forward P/E of 18.43.
Investors should also note that ABT has a PEG ratio of 1.65 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.52.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.